Which stock wins in a head-to-head matchup between these two clinical-stage biotechs?
News & Analysis: Inovio Pharmaceuticals
More revenue, more cash, lower expenses, and a lot of pipeline activity were the major stories for the biotech in Q1.
INO earnings call for the period ending March 31, 2019.
These three penny stocks have enormous upside potential, but they each come with a hefty dose of risk.
INO earnings call for the period ending December 31, 2018.
A new debt offering weighed on the biotech's shares last month.
Investors are not impressed with the biotech's latest plan to raise cash.
Inovio's stock has reclaimed a good chunk of its lost ground from last month's sell-off. Can it continue to surge?
Positive data published in a major cancer journal boosts the clinical-stage biotech stock.
The vaccine maker has been achieving steady progress with its lead candidate.